EDS-01 is under clinical development by Chengdu Wonho Biology Engineering and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect EDS-01’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 15 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EDS-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

EDS-01 overview

EDS-01 is under development for the treatment of advanced head and neck cancer squamous cell carcinoma, nasopharyngeal cancer. It is administered through intratumoral route. The therapy is a recombinant adenovirus type 5-recombined human endostatin gene.

Quick View EDS-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • EDS-01
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.